Last update: Feb. 10, 2019

8-Ethyl-5,8-dihydro-5-oxo-2-(piperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxylic acid

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Antibiotic of the quinolone type, active in vitro against Pseudomonas aeruginosa, structurally related to nalidixic acid.
It has been used orally and intravenously (two daily doses) to treat urinary tract infections from Gram-negative bacteria (Shimizu M 1975).

SInce the last update we have not found published data on its excretion in breastmilk.

Low toxicity in humans has been reported (Azierta 2016).

This product has very few bibliographical references.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity or glucose-6-phosphate dehydrogenase deficiency.

The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to alteration of the intestinal flora (Ito 1993).


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

8-Ethyl-5,8-dihydro-5-oxo-2-(piperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxylic acid is Pipemidic Acid in Chemical name.

Is written in other languages:

8-Ethyl-5,8-dihydro-5-oxo-2-(piperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxylic acid is also known as

Group

8-Ethyl-5,8-dihydro-5-oxo-2-(piperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxylic acid belongs to this group or family:

Tradenames

Main tradenames from several countries containing 8-Ethyl-5,8-dihydro-5-oxo-2-(piperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxylic acid in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 93 %
Molecular weight 303 daltons
Protein Binding 39 %
VD 1,7 l/Kg
Tmax 1,1 hours
T1/2 3,5 hours

References

  1. Azierta. Pipemidic acid. Drug Summary. 2016 Full text (in our servers)
  2. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  3. Klinge E, Männistö PT, Mäntylä R, Mattila J, Hänninen U. Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. Antimicrob Agents Chemother. 1984 Abstract
  4. Shimizu M, Nakamura S, Takase Y, Kurobe N. Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother. 1975 Abstract
  5. Shimizu M, Takase Y, Nakamura S, Katae H, Minami A. Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother. 1975 Abstract

Total visits

223

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM